{"organizations": [], "uuid": "c69176a9c468fd7e7219a13935e0b30df470adfa", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180208.html", "section_title": "Archive News &amp; Video for Thursday, 08 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-case-western-reserve-sangamo-thera/brief-case-western-reserve-sangamo-therapeutics-get-11-mln-nih-grant-idUSFWN1PX11P", "country": "US", "domain_rank": 408, "title": "BRIEF-Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.163, "site_type": "news", "published": "2018-02-07T20:45:00.000+02:00", "replies_count": 0, "uuid": "c69176a9c468fd7e7219a13935e0b30df470adfa"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-case-western-reserve-sangamo-thera/brief-case-western-reserve-sangamo-therapeutics-get-11-mln-nih-grant-idUSFWN1PX11P", "ord_in_thread": 0, "title": "BRIEF-Case Western Reserve, Sangamo Therapeutics get $11 Mln NIH Grant", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "sangamo therapeutics", "sentiment": "negative"}, {"name": "brief-case western reserve", "sentiment": "negative"}, {"name": "nih grant feb", "sentiment": "negative"}, {"name": "sangamo therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 7 (Reuters) - Sangamo Therapeutics Inc:\n* CASE WESTERN RESERVE AND SANGAMO THERAPEUTICS ANNOUNCE $11 MILLION NIH GRANT FOR STUDY OF GENE-EDITED T CELLS FOR VIRAL ERADICATION OF HIV\n* NO SB-728-T PRODUCT-RELATED SERIOUS ADVERSE EVENTS WERE REPORTED IN SANGAMOâ€˜S SB-728-T CLINICAL TRIALS\n* CO WILL BE CONTRIBUTING MATERIALS, EQUIPMENT, AND MANUFACTURING EXPERTISE FOR STUDY, WHICH IS EXPECTED TO BEGIN IN 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-07T20:45:00.000+02:00", "crawled": "2018-02-09T05:56:39.000+02:00", "highlightTitle": ""}